Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

1.

Validity of gout diagnosis in Swedish primary and secondary care - a validation study.

Dehlin M, Stasinopoulou K, Jacobsson L.

BMC Musculoskelet Disord. 2015 Jun 16;16:149. doi: 10.1186/s12891-015-0614-2.

2.

Smoking is associated with reduced leptin and neuropeptide Y levels and higher pain experience in patients with fibromyalgia.

Bokarewa MI, Erlandsson MC, Bjersing J, Dehlin M, Mannerkorpi K.

Mediators Inflamm. 2014;2014:627041. doi: 10.1155/2014/627041. Epub 2014 Aug 14.

3.

Cerebrospinal Flt3 ligand correlates to tau protein levels in primary Sjögren's syndrome.

Dehlin M, Bjersing J, Erlandsson M, Andreasen N, Zetterberg H, Mannerkorpi K, Bokarewa M.

Scand J Rheumatol. 2013;42(5):394-9. doi: 10.3109/03009742.2013.809143. Epub 2013 Jul 10.

PMID:
23837643
4.

Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis.

Andersson SE, Svensson MN, Erlandsson MC, Dehlin M, Andersson KM, Bokarewa MI.

PLoS One. 2012;7(10):e47668. doi: 10.1371/journal.pone.0047668. Epub 2012 Oct 17.

5.

Changes in pain and insulin-like growth factor 1 in fibromyalgia during exercise: the involvement of cerebrospinal inflammatory factors and neuropeptides.

Bjersing JL, Dehlin M, Erlandsson M, Bokarewa MI, Mannerkorpi K.

Arthritis Res Ther. 2012 Jul 9;14(4):R162. doi: 10.1186/ar3902.

6.

Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation.

Dehlin M, Andersson S, Erlandsson M, Brisslert M, Bokarewa M.

J Leukoc Biol. 2011 Oct;90(4):811-7. doi: 10.1189/jlb.1110640. Epub 2011 Jul 19.

7.

Intra-articular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis.

Dehlin M, Bokarewa M, Rottapel R, Foster SJ, Magnusson M, Dahlberg LE, Tarkowski A.

PLoS One. 2008;3(11):e3633. doi: 10.1371/journal.pone.0003633. Epub 2008 Nov 4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk